Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Reporter Virgin Islands.
Press releases published on April 16, 2025
Questor Announces December 31, 2024 Results
GlobeNewswire
·
April 16, 2025
CALGARY, Alberta, April 16, 2025 (GLOBE NEWSWIRE) -- Questor Technology Inc. (“Questor” or the “Company”) (TSX-V: QST) announced today its financial and operating results for the fourth quarter and year ended December 31, 2024. Questor’s audited …
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
GlobeNewswire
·
April 16, 2025
BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, President and co-CEO, will present a Company overview at the Life Science Innovation Northwest (LSINW) 2025 Conference on Wednesday, April 23, …
Vaxartto Present at World Vaccine Congress Washington 2025 on April 23
GlobeNewswire
·
April 16, 2025
SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine …
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
GlobeNewswire
·
April 16, 2025
SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson’s disease …
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
GlobeNewswire
·
April 16, 2025
CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts …
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025
GlobeNewswire
·
April 16, 2025
SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before …
Richtech Robotics Announces an Agreement to Purchase an Approximately 20,000 Square Foot Property to Expand Its Headquarters
GlobeNewswire
·
April 16, 2025
New Las Vegas-based facility plans to increase manufacturing and assembly capacity by 400% and accommodate further integration of domestic supply chain Las Vegas, NV, April 16, 2025 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (Nasdaq: RR) (“Richtech …
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
GlobeNewswire
·
April 16, 2025
Exemption from the $5.1 million repayment obligation strengthens LAVA’s balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V …
Avicanna Announces Revocation of Management Cease Trade Order
GlobeNewswire
·
April 16, 2025
TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
GlobeNewswire
·
April 16, 2025
LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced a development agreement to access …
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
GlobeNewswire
·
April 16, 2025
Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus CAMBRIDGE, …
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
April 16, 2025
WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that …
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
GlobeNewswire
·
April 16, 2025
CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that …
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
GlobeNewswire
·
April 16, 2025
CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that …
Tilray Brands Ranks #4 on the Brewers Association List of Top Producing Craft Brewers in the United States
GlobeNewswire
·
April 16, 2025
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Tilray Beverages, a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is pleased to announce that its U.S. Beverage division has achieved a significant milestone, ranking #4 on the Brewers …
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
GlobeNewswire
·
April 16, 2025
Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announced a major intellectual property …
Spectral Medical Completes Tigris Trial Enrollment
GlobeNewswire
·
April 16, 2025
157 patients enrolled Topline results expected to be released in August 2025 Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage …
DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application
GlobeNewswire
·
April 16, 2025
BROSSARD, Quebec, April 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial …
DIAGNOS annonce des avancées majeures dans sa certification de Cybersécurité par le Centre opérationnel de cyberdéfense (COCD) pour son application CARA System
GlobeNewswire
·
April 16, 2025
BROSSARD, Québec, 16 avr. 2025 (GLOBE NEWSWIRE) -- Diagnos inc. (« DIAGNOS » ou la « Société ») (Bourse de croissance TSX : ADK, OTCQB : DGNOF, FWB : 4D4A), un pionnier de la détection précoce de certains problèmes de santé ophtalmique à l'aide d'une …
Orezone Reports Q1-2025 Production and Hard Rock Expansion Update
GlobeNewswire
·
April 16, 2025
VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce its Q1-2025 gold production results and a construction update for the Stage I hard rock …